The present invention is focused on a method, kit and system for determining the presence or absence of minimal residual disease in a subject who has been treated for a proliferative disease wherein said method, kit and system comprise: (A) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject prior to treatment for said disease, to obtain a first list of characters reading from left to right; (B) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject after treatment for said disease, to obtain a second list of characters reading from left to right,
wherein when a nucleotide sequence is mutated it is a genetic marker for said proliferative disease; (C) determining, for each second list of characters obtained in step (B), the degree of similarity, DS, with each first list of characters obtained in step (A); (D) selecting, for each second list of characters obtained in step (B), the DS of highest value, DS.sub.HV; (E) adding up the number of second lists of characters which have a DS.sub.HV that is greater than a threshold value, T, to obtain L.sub.c, (F) adding up the total number of second lists of characters, L.sub.t; (G) calculating the level of minimal residual disease, MRD, according to any of the following formulae:

MRD=(L.sub.c×k)/(L.sub.t×D)

or

MRD=L.sub.c/L.sub.t

or

MRD=g×L.sub.c×(D/k)/L.sub.t.sup.2; (H) determining (i) the minimum variant read frequency, min VRF, of said genetic marker, (ii) the limit of detection, D-limit, of said genetic marker (iii) the average mutation noise, avMut and (iv) the average position noise, avPos; (I) determining the experimental sensitivity, ES, from the greater of the min VRF, D-limit, avMut and avPos or from the greater of min VRF and D-limit; (J) determining the presence or absence of minimal residual disease in said subject

The disclosure includes: acquiring first data; grouping the first data to obtain K packet sub-data; inputting a preset primer into a random generator to obtain 4T random number sequences, 4.sup.T>K; determining the packet sub-data corresponding to the ith random number sequence, and performing exclusive or (XOR) operation on the determined packet sub-data to obtain data information DATAi, and obtaining a DNA molecular chain according to the data information DATAi, the preset primer and the generation times capacity of the random generator; performing DNA sequence synthesis on the plurality of DNA molecular chains to obtain target storage data. In the disclosure, in the process of coding the first data to obtain a DNA molecular chain, a random generator is added to greatly simplify the coding process and implement efficient and accurate coding on the first data. The disclosure may be widely applied to a field of data storage technologies.

The present invention relates to technologies for preparing an optimal combination of oligonucleotide sets used to simultaneously detect a plurality of target nucleic acid molecules. Unlike a conventional method of checking whether a dimer is formed in all candidate combinations of oligonucleotide sets, the present invention is capable of providing a combination of oligonucleotide sets used to detect a plurality of target nucleic acid molecules with speed and accuracy, by replacing only an oligonucleotide set with dimer formation in a first reference combination of oligonucleotide sets to provide, as a new reference combination, a combination with a reduction in dimer formation compared with the first reference combination, and replacing only an oligonucleotide set with dimer formation in the new reference combination to provide a combination with all dimers removed.

The present invention relates to technologies for preparing an optimal combination of oligonucleotide sets used to simultaneously detect a plurality of target nucleic acid molecules. Unlike a conventional method of checking whether a dimer is formed in all candidate combinations of oligonucleotide sets, the present invention is capable of providing a combination of oligonucleotide sets used to detect a plurality of target nucleic acid molecules with speed and accuracy, by replacing only an oligonucleotide set with dimer formation in a first reference combination of oligonucleotide sets to provide, as a new reference combination, a combination with a reduction in dimer formation compared with the first reference combination, and replacing only an oligonucleotide set with dimer formation in the new reference combination to provide a combination with all dimers removed.

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, nucleic acid molecules, such as cell-free nucleic acids, can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and/or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

The present application provides multiplex digital polymerase chain reaction (dPCR) assays such as multiplex drop-off dPCR assays, methods, systems, and kits. The methods described herein are useful in a variety of applications, such as detection of microsatellite instability and quantification of site-specific genome-edited products.

The present application provides multiplex digital polymerase chain reaction (dPCR) assays such as multiplex drop-off dPCR assays, methods, systems, and kits. The methods described herein are useful in a variety of applications, such as detection of microsatellite instability and quantification of site-specific genome-edited products.

Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.

Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.

A data sifting method applied to a growth type curve including a plurality of data points, and includes: calculating a plurality of first derivative values corresponding to the data points; searching at least one local maximum value from the first derivative values; determining whether a part of the first derivative values adjacent to the at least one local maximum value are all positive; determining one of the first derivative values after a predetermined effective cycle number or the at least one local maximum value as a target maximum value according to a determination result; deriving a basic cycle number according to a target cycle number corresponding to the target maximum value; and setting a baseline of the growth type curve according to the basic cycle number to calculate a first Cq value according to the adjusted growth type curve. The present disclosure further provides a data sifting apparatus.